April 24, 2026 Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
April 24, 2026 IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 24, 2026 A.D.A.M. Innovations Unveils GeneLock™: The World’s First Genetic Data Protection Platform
